Eli Lilly Stock Jumps on Blockbuster Earnings, Fueled by Weight-Loss Drug Frenzy
Shares of Eli Lilly surged nearly 10% after the pharmaceutical giant smashed fourth-quarter estimates and issued a bullish 2026 outlook, powered by unprecedented demand for its GLP-1 drugs Mounjaro and Zepbound.